These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 23611226)
1. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review]. Qu SQ; Wang Y; Sun XJ Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226 [No Abstract] [Full Text] [Related]
2. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352 [TBL] [Abstract][Full Text] [Related]
3. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167 [TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder. Ng HJ; Tan DC; Yiu RC; How GF Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504 [TBL] [Abstract][Full Text] [Related]
5. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Helbig G; Kyrcz-Krzemień S Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127 [No Abstract] [Full Text] [Related]
6. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Pitini V; Sturniolo G; Cavallari V; Arrigo C Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645 [No Abstract] [Full Text] [Related]
7. Detection of FIP1L1-PDGFRA fusion by FISH. Ma ES; Wong KF; Wong CL; Siu LL Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982 [No Abstract] [Full Text] [Related]
8. Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib. Volz HC; Weiss C; Lossnitzer D; Zankl AR; Perz JB; Dengler TJ; Katus HA; Hardt SE Int J Cardiol; 2011 Sep; 151(3):e90-2. PubMed ID: 20609486 [No Abstract] [Full Text] [Related]
9. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119 [TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901 [No Abstract] [Full Text] [Related]
11. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Cools J Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297 [TBL] [Abstract][Full Text] [Related]
12. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Metzgeroth G; Erben P; Martin H; Mousset S; Teichmann M; Walz C; Klippstein T; Hochhaus A; Cross NC; Hofmann WK; Reiter A Leukemia; 2012 Jan; 26(1):162-4. PubMed ID: 21818111 [No Abstract] [Full Text] [Related]
13. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504 [TBL] [Abstract][Full Text] [Related]